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Abstract 
High density lipoproteins (HDL) promote the efflux of excess cholesterol from peripheral tissues to the liver for excretion. This ability is 
responsible for the most relevant anti-atherogenic effect of HDL. The ability of HDL to promote cholesterol efflux results also in the 
modulation of a series of responses in the immune cells involved in atherosclerosis, including monocyte-macrophages, B and T lymphocytes. 
Furthermore, during inflammation, the composition of this class of lipoproteins varies to a large extent, thus promoting the formation of 
dysfunctional HDL. The aim of this review is to discuss the emerging role of HDL in modulating the activity of immune cells and 
immune-inflammatory mediators during atherogenesis.  
J Geriatr Cardiol 2012; 9: 401−407. doi: 10.3724/SP.J.1263.2011.12282 
Keywords: High density lipoproteins; Apolipoprotein; Sphingosine-1-phosphate; Immune response  
 
 
1  Introduction  
Atherosclerosis and its clinical manifestations are the 
leading causes of morbidity and mortality in the Western 
World. For decades, atherosclerosis has been considered 
only as a disease associated with dyslipidemia.[1]   
More recently, both preclinical and clinical research has 
provided important evidence that inflammation and immune 
response are integral components of atherogenesis. There-
fore, atherosclerosis is now considered a chronic immune- 
inflammatory disease characterized by the presence of im-
mune cells during all stages of the progression of athero-
sclerotic plaque.[2]  
During the early phase of the disease, an endothelial 
injury initiates the entire process. According to the “oxid-
ation hypothesis,” endothelial dysfunction causes the reten-
tion of low-density lipoproteins (LDL) in the intima where 
they undergo oxidative modifications.[1] These modified 
lipids induce the expression of adhesion molecules, chemo-
kines, proinflammatory cytokines, and other mediators of 
inflammation. Then, leucocytes, penetrated into subendo-
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thelial space, actively participate to perpetuate local inflam-
matory response. 
The monocytes-macrophages express scavenger rece-
ptors for modified lipoproteins, permitting them to ingest 
lipid and become foam cells. In addition to monocyte chem-
oattractant protein-1 (MCP-1), macrophage colony-stimu-
lating factor (M-CSF) contributes to the differentiation of 
the blood monocyte into the macrophage foam cell.[1]  
T cells likewise encounter signals that cause them to 
elaborate inflammatory cytokines such as interferon and 
tumor necrosis factor that in turn can stimulate macrophages 
as well as vascular endothelial cells and smooth muscle cells 
(SMCs).[2]  
As this inflammatory process continues, the activated 
leukocytes and arterial cells can release fibrogenic medi-
ators, including a variety of peptide growth factors that can 
promote replication of SMCs and contribute to elaboration 
by these cells of a dense extracellular matrix, characteristic 
of the more advanced atherosclerosis lesion.[1]  
2 High density lipoproteins (HDL) 
HDL possess a number of physiological activities. Ma-
ture HDL present a hydrophobic core composed of chole-
steryl esters and triglycerides with proteins embedded in a 
lipid monolayer composed mainly of phospholipids and free 
cholesterol. HDL contain several apolipoproteins including 
apolipoprotein A-I (apoA-I) and apoA-II, the two main 
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proteins, and a large number of less abundant proteins 
including apoCs, apoE, apoD, apoJ and some enzymes such 
as lecithin-cholesterol acyltransferase, serum paraoxonase 
(PON1) and platelet-activating factor acetylhydrolase 
(PAF-AH).[3] The most relevant function of HDL is to 
promote the efflux of excess cholesterol from peripheral 
tissues to the liver for excretion,[4,5] a pathway known as 
reverse cholesterol transport (RCT). The efflux of 
cholesterol is important for maintaining cellular cholesterol 
homeostasis. This process is most likely compromised in the 
atherosclerotic lesion also because the development of 
atherosclerosis is usually associated with low HDL-cholesterol. 
Multiple mechanisms for efflux of cell cholesterol exist. 
Efflux of free cholesterol via aqueous diffusion occurs with 
all cell types but is inefficient. Efflux of cholesterol is 
accelerated when scavenger receptor class-B type I (SR-BI) 
is present in the cell plasma membrane. Both diffusion- 
mediated and SR-BI-mediated efflux occur to phospholipid- 
containing acceptors (i.e., HDL and lapidated apolipo-
proteins). In both cases, the flux of cholesterol is bidirec-
tional, with the direction of net flux dependant on the 
cholesterol gradient. The adenosine triphosphate binding 
cassette transporter AI (ABCA1) and GI (ABCG1) mediate 
efflux of both cellular cholesterol and phospholipid. In 
contrast to SR-BI-mediated flux, efflux via ABCA1 and 
ABCG1 are unidirectional, occurring to lipid-poor apolipo-
proteins.[6] Of note, these transporters are clustered together 
with many other functional proteins [including B and T cell 
receptors (BCR and TCR), sphingosine-1-phosphate rece-
ptors (S1PR)] in cellular membrane micro-domains called 
lipid rafts.[7] Lipid rafts are regions of membranes with a dis- 
tinct, characteristic structural composition and that appear to 
act as platforms to co-localize proteins involved in intrace-
llular signaling pathways. The organization of membranes 
into such micro-domains recognizes that, far from being 
randomly arranged, lipids may actually be highly organized 
within different parts of the membrane, and that this organi-
zation influences the way membrane proteins are distributed. 
Rafts are particularly rich in sphingolipids and cholesterol, 
and the side chains of the phospholipids present are usually 
highly enriched in saturated fatty acids compared with the 
surrounding non-raft regions of the membrane. Enrichment 
of phospholipids with saturated fatty acids allows for the 
close packing of lipids within rafts. As a result of the pre-
sence of cholesterol and saturated fatty acids, lipid rafts are 
more ordered and less fluid than the surrounding membrane. 
Cytoplasmic proteins that are covalently modified by sat-
urated fatty acids (palmitoyl or myristoyl moieties) and cell 
surface proteins that are attached via a glycosyl phosphatidyl- 
inositol anchor are highly concentrated within lipid rafts.  
Many proteins involved in signal transduction, such as Src 
family kinases, G proteins, growth factor receptors, mitogen- 
activated protein kinases (MAPK), and protein kinase C, are 
predominantly found in lipid rafts, which appear to act as sig-
naling platforms by bringing together (i.e., co-localizing) var-
ious signaling components, thus facilitating their interaction.[8]  
The integrity of the lipid raft structure is a fundamental 
requirement for the correct functionality of all the present 
proteins. Thus, it can be understood why lipid rafts are the 
key structure responsible for the remarkable ability of HDL 
to regulate a number of physiological processes, including 
innate and adaptive immune responses. 
In addition, apolipoproteins, lipids and enzymes carried 
by HDL can also modulate endothelial functions and have 
antioxidant activities that inhibit the oxidative modification 
of LDL, thereby reducing the atherogenic potential of these 
lipoproteins.[9] Of note, HDL is the predominant lipoprotein 
class in several species (from fish to ape) including those 
resistant to the development of atherosclerosis or cardiova-
scular diseases. Furthermore, the main constituent of HDL, 
apoA-I, is highly conserved throughout evolution,[10] as is 
the ability of HDL to modulate cholesterol bioavailability at 
the cellular level.[11] Cholesterol modulation in cells has also 
been associated with the ability of HDL to modulate 
hematopoietic stem cell maturation.[7,11–13] Other players of 
the immune response are modulated by HDL. HDL induce 
the expression of pentraxin 3 (PTX3)[14] which is involved 
in controlling leukocyte recruitment.[15] HDL induce PTX3 
mRNA expression and protein release, whereas no effect 
was observed on CRP and SAP expression. This effect is 
mainly dependent on the activation of the lysosphingolipid 
receptor-PI3K/Akt axis and is mimicked by sphingosine-1- 
phosphate and other S1P mimetics.[14] In vivo, an increased 
expression of PTX3 mRNA was detected in the aorta of 
transgenic mice overexpressing human apoA-I, compared to 
apoA-I knock-out mice and plasma levels of PTX3 are signi-
ficantly increased in C57BL/6 mice injected with HDL.[14] 
Of note, PTX3 deficiency is associated with cardiovascular 
disorders including atherosclerosis.[16,17] We have demon-
strated that PTX3 deficient animals with the apolipoprotein 
E-/- background, develop larger and more inflamed atherosc-
lerotic lesions compared to control animals.[17]  
The aim of this brief review is to discuss the emerging 
role of HDL in modulating the activity of immune cells and 
immune-inflammatory mediators during atherogenesis. 
3 Endotoxemia and acute phase response 
In the acute phase response, HDL-cholesterol and apoA-I 
levels are reduced in humans.[18,19] The quick change in 
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HDL and apoA-I during acute response is commonly per-
ceived as an adaptation of this system to inflammation. While 
the inflammatory response represents a host defense to inva-
ding pathogens, uncontrolled systemic inflammation can lead 
to serious complications, such as disseminated intravascular 
coagulation, tissue damage, and endotoxic shock.[20] For in-  
stance, lipopolysaccharides (LPS) are the primary cause of 
Gram-negative-induced sepsis. LPS, through its interaction 
with the LPS-binding protein (LBP)-CD14-TLR4 (Toll like 
receptor 4) complex, activates macrophages, causing a mas-
sive release of inflammatory cytokines.[21] LBP binds pre-
ferentially to HDL.[22] Of note, intravenous infusion of recon- 
stituted HDL protects mice from the toxic effect of LPS,[23] 
an effect less evident in rabbits.[24] Furthermore, protection 
from LPS toxicity was achieved in transgenic mice with a 
two fold elevation of HDL;[23] this animal model shows more 
LPS bound to HDL, lower plasma cytokine levels and imp-  
roved survival rates compared to control mice.  
Also in humans, low HDL levels are associated with 
increased sensitivity toward inflammatory stimuli as reflec-
ted by enhanced inflammatory and coagulation responses on 
endotoxin challenge.[25] Transgenic animals lacking apoA-I, 
exhibit an increased lipopolysaccharide-driven mortality.[22,26] 
Because of the significant protection against LPS-induced 
damage, reconstituted HDL and apoA-I mimetics represent 
an interesting approach to improve the control of endoto-
xemia.[23,27] Milestones studies pointed out that the capacity 
of HDL to bind LPS is 10- to 1000-fold above the LPS con-
centrations reported in studies of septic patients.[28,29] It is 
therefore unlikely that the maximal increase in HDL levels 
achieved (2 to 3-fold) could result in rescue from LPS 
endotoxemia and lethality only through LPS sequestration 
and hepatic clearance. This has been widely investigated in 
the last two decades showing a series of additional HDL 
effects on the cells and the events involved in the immune- 
inflammatory response.  
Following an infection, circulating HDL, known as “acute- 
phase HDL” (sometimes regarded also as pro-inflammatory 
HDL), show altered chemical and physical characteristics.  
Mediators of inflammation, such as tumor necrosis factor 
(TNF)-α and interleukin (IL)-6, induce expression of serum 
amyloid A[30] and group IIA secretory phospholipase A2 
(sPLA2-IIA),[31] which dramatically alter HDL apolipop-
rotein content and levels, respectively. Furthermore, during 
inflammation, the composition of HDL is modified by the 
binding of acute phase products, such as serum amyloid A 
(SAA) and ceruloplasmin.[32] The content of proteins ass-
ociated with HDL is altered so that PON1 levels decrease, 
thus reducing the anti-oxidant properties of HDL,[33] while 
PAF-AH increases leading to an increase of pro-atherogenic 
lipids.[34,35] These structural changes in the HDL induce 
functional lipoprotein alterations that can account, at least in 
part, for the increased risk of atherosclerosis observed during 
the acute phase response. For instance, the antioxidant 
properties of HDL and its function as a cholesterol acceptor 
are significantly reduced in subjects undergoing an acute 
phase response.[36–38] During the acute phase, SAA rapidly 
associates with HDL becoming the main protein,[39,40] acco-
unting for 17% to 87% of the total apoproteins in acute-phase 
HDL. 
4 HDL and immune cells  
One of the key events in the atherogenic process is the 
development of foam cells following monocytes-derived 
macrophage lipid engulfment.[41,42] Following cholesterol 
deposition, macrophages activate cholesterol removal mech-
anisms through the interaction of ABCA1 and ABCG1 and 
apoA-I or HDL.[43,44] This interaction negatively modulates 
macrophage expression of inflammatory mediators, such as 
MCP-1 and CD11b,[45] and inhibits the lymphocyte prolifera-
tive response.[46,47] Furthermore, macrophages lacking ABCA1 
and/or ABCG1 exhibit an increased lipid raft formation.[48] 
The function of the lipid raft is correlated to its cholesterol 
content and the removal of cholesterol from these micro- 
domains can interfere with signaling pathways in immune 
cells,[49] and with antigen-presenting function.[50] One main 
function of lipid rafts is the regulation of signaling through the 
T cell receptors.[51–53] As an example, the localization of 
major histocompatibility (MHC) class II molecules in lipid 
rafts[54–56] facilitate the function of antigen-presenting cells 
and is essential for T cell activation, as this process decreases 
the amount of antigen necessary for T cell activation.[57,58] For 
this reason, cholesterol depletion from lipid rafts can inhibit 
T cell activation. Both HDL and apoA-I remove cholesterol 
from lipid rafts via ABCG1, SR-BI and ABCA1, reducing the 
inflammatory response in macrophages and inhibiting the 
ability of antigen-presenting cells to stimulate T-lympho-
cytes.[48,59] 
Dendritic cells (DCs) are immune cells whose main fun-
ction is to process an antigen, present it on their surface and 
activate T-cells. DCs are present in atherosclerotic lesions[60] 
and co-localize with T-cells.[61] DCs produce mediators of 
the innate immune system and increase the expression of co- 
stimulatory molecules, including CD40, CD80 and CD86,[62,63] 
which are essential for T-cell responses. ApoA-I inhibits 
DCs differentiation from monocytes, inhibits the ability of 
DCs to secrete IL-12 when stimulated with anti-CD40 and 
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interferon γ (IFNγ), and increases the production of two 
inhibitors of DC differentiation, such as IL-10 and PGE2.[64]  
Atherosclerotic lesions also contain cells of the adaptive 
immune system, in particular T cell subsets known to modu-
late inflammatory process in atherogenesis. BCR and TCR 
are localized in lipid rafts. In resting cells, BCR and TCR 
are excluded from lipid rafts. Upon activation, these rece-
ptors associate with membrane micro-domains, resulting in 
a spatial organization of receptor signaling.[65] The associa-
tion of BCR and TCR with lipid rafts is dependent on mem-
brane cholesterol content and changes in lipid raft compo-
sition and structure induced by HDL or apoA-I can affect 
receptor activities.[66,67] Both B and T cells egression from 
lymph nodes is also affected by lysosphingolipids, in par-
ticular S1P, a component of HDL.[68–70] S1P carried by HDL 
positively correlates with HDL-cholesterol, apoA-I, and 
apoA-II levels. Furthermore, S1P is enriched in small dense 
subclass 3 of HDL (HDL3).[71] Modulation of S1P1 rece-
ptors by a synthetic S1P analogue, FTY720, in LDL-R 
knockout mice resulted in a marked decrease of peripheral 
blood lymphocytes, thus preventing their recruitment into 
sites of inflammation.[72,73] Finally, FTY720 reduces the 
delivery of scavenged lipoprotein cholesterol to the endo-
plasmic reticulum and facilitates its release to physiological 
extracellular acceptors, resulting in decreased cholesterol 
toxicity in macrophages.[74] S1P1 is the main S1P receptor 
involved in the egress of T cells from lymphoid organs 
(Table 1).[58,59] In transgenic mice, S1P1 inhibited the 
differentiation of regulatory T cells (Tregs) while promoting 
the development of T helper type 1 (Th1) cells in a reci-
procal manner.[70] We recently showed, in humans, an 
inverse relation between a HDL and CD3+ CD4+CD25high 
CD127low Treg cell levels, while no correlation was found 
between Tregs and LDL cholesterol, total cholesterol or 
triglyceride levels.[75] In animal models, other mechanisms 
by which HDL can modulate Treg have been proposed. 
ApoA-I administration reduces inflammation in LDL rece-
ptor-/-, apoA-I-/- mice by decreasing the numbers of lymph 
node immune cells, by increasing Tregs and decreasing the 
percentage of effector memory T cells.[76] All these data 
suggest that some of the effects of HDL on atherosclerosis 
may result from the modulation of molecules and cells that 
act as sensors of the immune-inflammatory balance during 
atherogenesis.  
Table 1.  Immune cells and atherosclerosis: effects of HDL and its components.  
 Macrophages/Dendritic cells Lymphocytes 
HDL Inhibition of antigen-presenting cell function due to 
displacement of MHCII from lipid rafts 
Suppression of the LPS-induced type I IFN response. 
Reduction of inflammatory mediators expression 
Prevention of hematopoietic stem and multi-potential progenitor 
cell proliferation 
Reduction of BCR and TCR activity 
Inhibition of lymphocytes proliferative response  
ApoA-I Inhibition of antigen-presenting cell function due to 
displacement of MHCII from lipid rafts 
Inhibition of dendritic cells differentiation from macrophages 
Reduction of DC ability to stimulate T-cells 
Cholesterol depletion from lipid rafts 
Reduction of co-stimulatory molecule expression in DCs 
Reduction of TLR4 and CD14 expression 
Macrophage arterial trafficking inhibition by apoA-I mimetic 
peptide D-4F  
Reduction of BCR and TCR activity 
Reduction of lymph node immune cell number; increase of Treg; 
decrease of effector memory T cells percentage in LDLr-/-, 
apoA-I-/- mice 
Inhibition of T-cell activation and proliferation in 
hypercholesterolemic mice 
Inhibition of leukocytosis 
Prevention of cholesterol-induced lymphocyte accumulation, 
activation and proliferation in peripheral lymph nodes of  
LDLr-/-, apoA-I-/- mice  
S1P/S1PRs Inhibition of LPS-induced response and cholesterol toxicity by 
the S1P synthetic analogue FTY720 
Reduction of peripheral blood lymphocyte; reduction of CD3+ 
T-cell content in atherosclerotic plaque 
Suppression of lymphocyte proliferation by FTY720 
Inhibition of Treg differentiation 
Switch Treg to Th1 development 
Apo: apolipoproteins; BCR: B cell receptors; HDL: high density lipoproteins; IFN: interferon; LDL: low-density lipoproteins; LPS: lipopolysaccharides; MHC: 
major histocompatibility complex; S1P: sphingosine-1-phosphate; TCR: T cell receptors; TLR: toll like receptor; Treg: regulatory T cells. 
 
5 Conclusions 
HDL acts as reservoir for a number of biologically active 
substances that may impact the immune system during 
atherogenesis. Of note, modifications in the lipid and lipop-
rotein profiles are highly correlated to lymphocyte T effect-
tor memory cells and the risk of cardiovascular events.[73] 
Therefore, the ability of HDL to promote cholesterol efflux 
results in the modulation of a series of responses in the 
immune cells involved in atherosclerosis, including mono-
cyte-macrophages, B and T lymphocytes. Since the HDL 
composition varies to a large extent during inflammation, 
the understanding of how these interactions take place and 
how biologically active substances can be delivered to 
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relevant targets during atherogenesis is of great interest. 
Drugs targeting HDL levels and activity represent one of the 
emerging frontiers in lipidology and pharmacology. Whe-
ther these drugs impact the immune-inflammatory response 
in atherosclerosis will be extensively investigated in sub-
sequent years.  
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